Basic Information
LncRNA/CircRNA Name | n346372 |
Synonyms | NA |
Region | NA |
Ensemble | NA |
Refseq | NA |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | bladder cancer |
ICD-0-3 | C67 |
Methods | qPCR, other |
Sample | bladder cancer tissues and cell lines |
Expression Pattern | up-regulated |
Function Description | In addition, the results of fluorescence in situ hybridization analysis of bladder cancer cells and tissues demonstrated that lncRNA-n346372 is located in the cytoplasm, and the expression of lncRNA-n346372 in bladder cancer tissues was significantly increased compared with the paired normal tissues. Following a ?2 test with common clinical variables among the patients, the expression level of lncRNA-n346372 was demonstrated to be positively associated with advanced tumor stage and poor histological differentiation of bladder cancer. Kaplan-Meier survival analysis revealed that patients with high expression of n346372 were more likely to have a poor prognosis compared with patients with low n346372 expression. Finally, univariate and multivariate analyses indicated that the relative level of n346372, apart from tumor stage and histological grade, may serve as an independent prognostic factor of bladder cancer. |
Pubmed ID | 30365104 |
Year | 2018 |
Title | Overexpression of Long Non-coding RNA n346372 in Bladder Cancer Tissues Is Associated With a Poor Prognosis |
External Links
Links for n346372 | GenBank HGNC NONCODE |
Links for bladder cancer | OMIM COSMIC |